Nordic Bioscience Welcomes Investment from KKR for Next Phase of Growth
KKR s investment will support Nordic Bioscience with commercialization and the global expansion of its R&D services, diagnostics platform, leading patent portfolio and drug development pipeline
Nordic Bioscience A/S, a Danish company and world leader in biomarker development, announced today the signing of an investment from KKR, a leading global investment firm. KKR will acquire a minority equity stake in Nordic Bioscience from existing shareholders and will support the company in accelerating its global growth.
Nordic Bioscience has world-leading knowledge and ownership of biomarkers, measurable indicators of biological change or response used for the development of diagnostic tools and identification of new drug candidates.